Unknown

Dataset Information

0

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).


ABSTRACT: PURPOSE:Aromatase inhibitors are the most commonly prescribed adjuvant endocrine therapy for hormone-dependent early breast cancer in postmenopausal women. Among Canadian Cancer Trials Group MA.27 participants, anastrozole and exemestane had comparable 5-year event-free survival. This companion study examined differences in patient-reported treatment-related symptoms (TRS) and health-related quality of life (HRQL) among postmenopausal women randomized to anastrozole or exemestane. METHODS:MA.27 participants (N = 686, of 7576) randomized to 5 years of anastrozole (1 mg/day, n = 371, Arm A) or exemestane (25 mg/day, n = 315, Arm E) completed the 56-item Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) questionnaire to assess TRS and HRQL. The FACT-ES was completed at baseline, 3, 6, 12, and 24 months. RESULTS:No significant differences in FACT-ES median scores measuring TRS and HRQL were observed between treatment arms at any time point. Change in TRS from baseline was statistically significant at 3, 6, 12, and 24 months. HRQL was stable over time in both arms. Greater TRS burden was associated with poorer HRQL (coefficient = 0.57, p < 0.001). Twenty percent of patients discontinued AI therapy by month 24 and 32% discontinued AIs at 4 years. In both arms, patients reporting more side effect bother prior to initiating study treatment had a higher risk of discontinuing treatment before completing protocol therapy (hazard ratio [HR] 1.29, 95% CI 1.08-1.55, p = 0.01). CONCLUSIONS:TRS and HRQL were comparable between anastrozole and exemestane. TRS negatively affect HRQL. Women who report being bothered by treatment side effects prior to initiating an AI are at increased risk for early treatment discontinuation.

SUBMITTER: Wagner LI 

PROVIDER: S-EPMC6092930 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).

Wagner Lynne I LI   Zhao Fengmin F   Goss Paul E PE   Chapman Judith-Anne W JW   Shepherd Lois E LE   Whelan Timothy J TJ   Mattar Bassam I BI   Bufill Jose A JA   Schultz William C WC   LaFrancis Irving E IE   Nagargoje Gauri G GG   Vemuri Radhakrishna R   Nikcevich Daniel A DA   Sledge George W GW   Cella David D  

Breast cancer research and treatment 20180217 3


<h4>Purpose</h4>Aromatase inhibitors are the most commonly prescribed adjuvant endocrine therapy for hormone-dependent early breast cancer in postmenopausal women. Among Canadian Cancer Trials Group MA.27 participants, anastrozole and exemestane had comparable 5-year event-free survival. This companion study examined differences in patient-reported treatment-related symptoms (TRS) and health-related quality of life (HRQL) among postmenopausal women randomized to anastrozole or exemestane.<h4>Met  ...[more]

Similar Datasets

| S-EPMC3612593 | biostudies-literature
| S-EPMC4289722 | biostudies-literature
| S-EPMC6669949 | biostudies-literature
| S-EPMC5363272 | biostudies-literature
| S-EPMC7469602 | biostudies-literature
| S-EPMC7501182 | biostudies-literature
| S-EPMC3201097 | biostudies-other
| S-EPMC3669502 | biostudies-other
| S-EPMC4352316 | biostudies-literature
| S-EPMC4565534 | biostudies-literature